Newman Dignan & Sheerar, Inc. Bristol Myers Squibb CO Transaction History

Newman Dignan & Sheerar, Inc.

$429 Million
Q2 2025

A detailed history of Newman Dignan & Sheerar, Inc. transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Newman Dignan & Sheerar, Inc. holds 18,008 shares of BMY stock, worth $827,467. This represents 0.19% of its overall portfolio holdings.

Number of Shares

18,008

Previous 17,969 0.22%

Holding current value

$827,467

Previous $1.1 Million 23.93%

% of portfolio

0.19%

Previous 0.3%

32 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Jul 18, 2025	BUY	$44.12 - $59.6 $1,720 - $2,324	39 Added 0.22%	18,008 $833,000
Q1 2025 May 14, 2025	BUY	$53.9 - $63.11 $17,355 - $20,321	322 Added 1.82%	17,969 $1.1 Million
Q4 2024 Jan 30, 2025	SELL	$51.92 - $59.94 $27,206 - $31,408	-524 Reduced 2.88%	17,647 $998,000
Q3 2024 Nov 12, 2024	BUY	$39.66 - $51.75 $36,209 - $47,247	913 Added 5.29%	18,171 $940,000
Q2 2024 Jul 15, 2024	SELL	$40.25 - $52.99 $126,264 - $166,229	-3,137 Reduced 15.38%	17,258 $716,000
Q1 2024 Apr 26, 2024	SELL	$47.98 - $54.4 $34,689 - $39,331	-723 Reduced 3.42%	20,395 $1.11 Million
Q4 2023 Feb 08, 2024	BUY	$48.48 - $57.85 $35,390 - $42,230	730 Added 3.58%	21,118 $1.08 Million
Q3 2023 Nov 07, 2023	SELL	$57.89 - $64.73 $58,237 - $65,118	-1,006 Reduced 4.7%	20,388 $1.18 Million
Q2 2023 Aug 02, 2023	BUY	$63.71 - $70.74 $191 - $212	3 Added 0.01%	21,394 $1.37 Million
Q1 2023 Apr 28, 2023	BUY	$65.71 - $74.53 $6,768 - $7,676	103 Added 0.48%	21,391 $1.48 Million
Q4 2022 Jan 20, 2023	BUY	$68.48 - $81.09 $29,583 - $35,030	432 Added 2.07%	21,288 $0
Q3 2022 Oct 18, 2022	BUY	$0.13 - $76.84 $17 - $10,450	136 Added 0.66%	20,856 $1.48 Million
Q2 2022 Aug 03, 2022	SELL	$72.62 - $79.98 $26,070 - $28,712	-359 Reduced 1.7%	20,720 $1.6 Million
Q1 2022 Apr 14, 2022	SELL	$61.48 - $73.72 $1,291 - $1,548	-21 Reduced 0.1%	21,079 $1.54 Million
Q4 2021 Jan 18, 2022	BUY	$53.63 - $62.52 $1,448 - $1,688	27 Added 0.13%	21,100 $1.32 Million
Q2 2021 Jul 28, 2021	BUY	$61.91 - $67.42 $70,082 - $76,319	1,132 Added 5.68%	21,073 $1.41 Million
Q1 2021 May 05, 2021	BUY	$59.34 - $66.74 $13,707 - $15,416	231 Added 1.17%	19,941 $1.26 Million
Q4 2020 Jan 29, 2021	BUY	$57.74 - $65.43 $8,661 - $9,814	150 Added 0.77%	19,710 $1.22 Million
Q3 2020 Oct 14, 2020	SELL	$57.43 - $63.64 $34,572 - $38,311	-602 Reduced 2.99%	19,560 $1.18 Million
Q2 2020 Aug 06, 2020	BUY	$54.82 - $64.09 $27,519 - $32,173	502 Added 2.55%	20,162 $1.19 Million
Q1 2020 Apr 20, 2020	SELL	$46.4 - $67.43 $36,656 - $53,269	-790 Reduced 3.86%	19,660 $1.17 Million
Q4 2019 Jan 15, 2020	SELL	$49.21 - $64.19 $30,510 - $39,797	-620 Reduced 2.94%	20,450 $1.31 Million
Q3 2019 Oct 21, 2019	SELL	$42.77 - $50.71 $173,132 - $205,274	-4,048 Reduced 16.12%	21,070 $1.07 Million
Q2 2019 Jul 31, 2019	SELL	$44.62 - $49.34 $23,648 - $26,150	-530 Reduced 2.07%	25,118 $1.14 Million
Q1 2019 Apr 09, 2019	SELL	$45.12 - $53.8 $65,694 - $78,332	-1,456 Reduced 5.37%	25,648 $1.22 Million
Q4 2018 Jan 24, 2019	SELL	$48.76 - $63.23 $8,142 - $10,559	-167 Reduced 0.61%	27,104 $1.41 Million
Q3 2018 Oct 25, 2018	BUY	$55.19 - $62.25 $662 - $747	12 Added 0.04%	27,271 $1.7 Million
Q2 2018 Jul 06, 2018	SELL	$50.53 - $62.98 $102,676 - $127,975	-2,032 Reduced 6.94%	27,259 $1.51 Million
Q1 2018 Apr 17, 2018	SELL	$59.92 - $68.98 $81,431 - $93,743	-1,359 Reduced 4.43%	29,291 $1.72 Million
Q4 2017 Jan 29, 2018	SELL	$59.94 - $65.35 $43,096 - $46,986	-719 Reduced 2.29%	30,650 $1.88 Million
Q3 2017 Oct 18, 2017	SELL	$55.23 - $63.74 $49,983 - $57,684	-905 Reduced 2.8%	31,369 $2 Million
Q2 2017 Aug 08, 2017	BUY	N/A	32,274	32,274 $1.8 Million

Others Institutions Holding BMY

# of Institutions

2,677

Shares Held

1.58B

Call Options Held

25.9M

Put Options Held

24.1M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $97.7B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Newman Dignan & Sheerar, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Newman Dignan & Sheerar, Inc. with notifications on news.

Account

Newman Dignan & Sheerar, Inc. Bristol Myers Squibb CO Transaction History